Table of Contents

Chairman’s Message .................................................................................................................. 1
CEO Report ................................................................................................................................. 2
2017 Foundation Research Funding Commitments and Investment Highlights ..... 3 – 4
Treasurer’s Report ....................................................................................................................... 6 – 8
Board of Directors ..................................................................................................................... 9
Scientific Advisory Board ........................................................................................................ 10 – 12
National Trustees ..................................................................................................................... 13 – 14
Senior Staff .............................................................................................................................. 15
National Chapters ..................................................................................................................... 16

Legacy Planning
Please consider, as part of your lasting legacy, remembering the Foundation Fighting Blindness in your will, trust, or other estate planning. For more information, visit our planned giving website at www.myplantofightblindness.org.
I’m pleased to welcome you to the 2017 Foundation Fighting Blindness Annual Report. While I have the privilege of opening this report, it takes a team effort to achieve FFB’s mission. I encourage you, our most loyal donors, to take a few minutes to read the full report. In doing so you will see how your generosity has helped fuel a revolution in inherited retinal disease science – one that puts us solidly into an era of clinical trials and on the cusp of providing treatments for some retinal degenerations!

FFB provides the all-important seed money to support the work of the world’s best retinal disease scientists. We propel their best ideas forward so they can be studied, attract larger funding investments from private and public sources, and, in a few cases, earn FDA approval!

This strategy has yielded strong dividends. One of the most significant was this past October’s recommendation by the U.S. Food and Drug Administration Advisory Committee on Cellular, Tissue, and Gene Therapies that Spark Therapeutics’ gene therapy for the treatment of RPE65 gene mutations be approved. This anticipated therapy will not only be life-changing for people with LCA caused by the RPE65 mutation, it will help move additional gene-based ocular and other treatments forward. See pages 3–5 for other highlights of the year and for a list of ongoing clinical trials that have their roots in FFB funding — 24 to date and across the spectrum of inherited retinal diseases.

What’s behind this amazing progress? We take your donated dollars and, through a review process involving the field’s leading researchers and clinicians, deploy them worldwide, leveraging your donation for additional investments. Give us $100 or $1,000 or $25,000, and we will carefully invest that money in research that we believe will not only improve the field’s understanding of how to treat retinal diseases but will also attract the larger investments required to bring those treatments to market.

Our current priority is moving more and more therapies that show promise in the lab to clinical trials to show safety and efficacy. We need your continued help to do so.

In closing I want to reiterate that fulfilling our mission to end blindness caused by inherited retinal disease takes a team. I want to thank the score of FFB researchers and clinicians who are working hard every day to find cures. I want to thank those experts who sit on FFB’s Research Oversight Committee and our Scientific Advisory Board for continually lending their expertise to the effort. I want to recognize the patients who courageously participate in clinical trials. Thanks as well to our hardworking staff. And, finally, I want to again thank our donors. Without you, none of the treatment progress FFB has helped create over the last four decades would have been possible.

Sincerely,

David Brint
I am thrilled to be writing my first CEO message as part of the Foundation’s annual report. Since joining the Foundation in October, I have been continually impressed by the depth and breadth of FFB’s impact on inherited retinal diseases and age-related macular degeneration research. This is truly a groundbreaking time in the search for cures, and I am proud to be part of an organization that will continue to be at the forefront of that charge.

What I’ve learned during my nearly 30-year career in biotechnology and drug development is what makes me so excited to be part of the Foundation’s dynamic team. Simply put, FFB, with the continued support of its donors and partners, has what it takes to solve the problem of vision loss due to retinal degenerative diseases.

What’s required? Funding is, of course, critical but so are strategic investment and collaborations. FFB’s strategy is rooted in five key strategies:

- Steward every donor gift prudently
- Support a broad portfolio of possible treatments
- Understand how a finding in one disease area or potential therapy helps inform other studies
- Foster teamwork/partnerships with industry
- Persist

Working together, we have all these necessary ingredients and a real opportunity to rewrite the life script for people living with retinal diseases. See page eight of this report for an overview of FFB’s research funding commitments during 2017. As these data demonstrate, our funding grants and investments – at research institutions worldwide – are supporting studies in many areas, including how the retina works, genetics, gene therapy, and cellular and molecular mechanisms.

Thank you for welcoming me to the team. I look forward to spending a lot of time during the coming months in the field attending FFB events, meeting our donors and chapter and walk leaders, and visiting our funded researchers. I am confident that, working together, we can make a real difference.

Sincerely,

Benjamin R. Yerxa
This year the Foundation continued its long-standing strategy of funding the most promising retinal science studies across the spectrum of these diseases. We also made several major investments in ongoing research through collaborations with industry and clinical partners.

The Foundation currently funds 75 projects at prominent laboratories and research clinical centers around the world. Listed below are a few of the significant developments and investments made by the Foundation during the past year. Following these summaries is a list of clinical trials currently underway which were made possible, in part, due to FFB support. Taken together, this growing number of clinical trials and the increasing number of FFB–industry collaborations demonstrate the ways in which FFB is helping to move treatments closer to the marketplace and to the patients who will benefit from them.

**FDA Advisory Committee Recommends Approval of RPE65 Gene Therapy**

The most exciting news of the year was the unanimous vote by the U.S. Food and Drug Administration’s Advisory Committee on Cellular, Tissue, and Gene Therapies to recommend FDA approval of voretigene neparvovec. The emerging treatment, developed by Spark Therapeutics and to be marketed as Luxturna™, is for people with vision loss from Leber congenital amaurosis and retinitis pigmentosa caused by RPE65 gene mutations. The treatment delivers functional copies of the RPE65 gene directly into the retina thereby compensating for the nonfunctional, mutated copies. FFB invested $10 million in research over two decades that made clinical trials for the gene therapy possible. At press time, the ultimate FDA decision on the treatment was expected by January 2018.

**SparingVision Formed to Advance Sight-Saving Protein**

The development of a treatment with the potential to save vision for people with retinitis pigmentosa by slowing the progression of the disease is getting a major boost thanks to the formation of the French biotech company SparingVision, to move it into a clinical trial and out to the international marketplace. The Foundation Fighting Blindness Clinical Research Institute (FFB-CRI) made an $8.2 million equity investment in the new company. A spinoff of the Institut de la Vision, SparingVision was established to clinically develop and commercialize a protein known as rod-derived cone viability factor (RdCVF). The emerging, vision-saving therapy performed well in several FFB-CRI-funded lab studies at the Institut de la Vision in Paris. SparingVision’s goal is to launch a clinical trial in 2019.

**Foundation Investing in Drug to Slow Many Forms of Retinitis Pigmentosa**

Sometimes, fighting blindness means helping people save the vision they have, or at least slowing disease progression enough so they can maintain useful vision for all of their lives. That’s the idea behind a promising, emerging drug for retinitis pigmentosa (RP) known as N-acetylcysteine-amide (NACA). The Foundation Fighting Blindness Clinical Research Institute announced an investment of up to $7.5 million to advance the potential therapy into and through a Phase 2 clinical trial. In several animal models, including previous FFB-funded lab studies of rodent models at Johns Hopkins University, NACA slowed retinal degeneration.

Nacuity Pharmaceuticals, Inc., a start-up company in Fort Worth, Texas, owns the rights to NACA for ophthalmology and will be
developing the drug with support from FFB-CRI. As part of its agreement with Nacuity, upon commercialization of NACA, FFB-CRI will be entitled to royalty payments from future NACA sales.

**FFB-CRI Launches Natural History Study for People with USH2A Mutations**

USH2A is a target for retinal-disease researchers because mutations in the gene are the most common cause of Usher syndrome type 2, which causes combined vision loss from retinitis pigmentosa (RP) and hearing loss from inner ear dysfunction. Also, USH2A mutations are a leading cause of RP without hearing loss (i.e., nonsyndromic).

A major challenge in providing prognoses for USH2A patients — and designing clinical trials for potential therapies — is the wide variability in the severity and rate of progression of the disease and its symptoms. Researchers have identified hundreds of USH2A mutations — misspellings in the patients’ genetic code. Some of these defects lead to RP only. Others cause Usher syndrome.

To gain a better understanding of how USH2A mutations affect the severity and progression of vision loss, the FFB-CRI has launched a four-year, $8 million natural history study of 120 people with USH2A mutations. The study — known as RUSH2A (“R” stands for “rate of progression”) — began in spring 2017 and will take place at about 20 clinical sites around the world.

RUSH2A investigators are using a variety of technologies to monitor changes in vision and retinal structure to document and analyze disease progression.

The results of RUSH2A will help USH2A therapy developers, including companies and research institutes, better design clinical trials by enabling them to enroll the patients who are most likely to respond to treatment. It may also help determine clinical trial sensitive and precise outcome measures to quickly determine if a therapy is working to save vision.

**Clinical Trials for Emerging Retinal Degenerative Disease Therapies**

**Select Trials as of Fall 2017**

Thanks to research advances made possible by the Foundation Fighting Blindness and research-funding organizations around the world, more clinical trials for retinal-disease therapies are underway than ever before. The following graphic is a snapshot of many of these studies. While not all these potential treatments will gain regulatory approval, the momentum in clinical development provides real promise for saving and restoring vision for everyone affected.

<table>
<thead>
<tr>
<th>Type</th>
<th>Disease Target</th>
<th>Emerging Therapy</th>
<th>Company</th>
<th>Phase</th>
<th>Trial Sites</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cell</td>
<td>Dry AMD</td>
<td>RPE cells on scaffold</td>
<td>Regenerative Patch Technologies</td>
<td>Phase 1/2</td>
<td>Five sites in Southern California</td>
</tr>
</tbody>
</table>
| Cell | Dry AMD        | RPE cells        | Cell Cure | Phase 1/2 | • Two U.S. sites  
|      |                |                  |         |       | • Four Israeli sites |
| Cell | RP             | Retinal progenitor cells | jCyte | Phase 2 | • University of California, Irvine  
|      |                |                  |         |       | • Retina-Vitreous Associates (L.A.) |
| Cell | RP             | Retinal progenitor cells | ReNeuron | Phase 1/2 | Massachusetts Eye and Ear Infirmary |
| Drug | Dry AMD        | Complement factor 3 inhibitor | Apellis | Phase 2 | Thirty-five sites in U.S., Australia, New Zealand |
| Drug | Stargardt disease | Emixustat hydrochloride | Acucela | Phase 2 | Retina Foundation of the Southwest (Dallas) |
| Drug | Stargardt disease | Deuterated vitamin A | Alkeus | Phase 2 | Seven U.S. Sites |
| Gene | Achromatopsia | CNGA3 gene therapy | AGTC | Phase 1/2 | • Five U.S. sites  
<p>|      |                |                  |         |       | • One Israeli site |</p>
<table>
<thead>
<tr>
<th>Gene</th>
<th>Therapy</th>
<th>Therapy Name</th>
<th>Sponsor(s)</th>
<th>Phase</th>
<th>Sites</th>
</tr>
</thead>
<tbody>
<tr>
<td>Achromatopsia</td>
<td>CNGB3 gene therapy</td>
<td>AGTC</td>
<td>Phase 1/2</td>
<td>Five U.S. sites</td>
<td></td>
</tr>
<tr>
<td>Achromatopsia</td>
<td>CNGB3 gene therapy</td>
<td>MeiraGTx</td>
<td>Phase 1/2</td>
<td>Moorfields Eye Hospital (UK)</td>
<td></td>
</tr>
<tr>
<td>Achromatopsia</td>
<td>CNGA3 gene therapy</td>
<td>University Hospital Tübingen</td>
<td>Phase 1/2</td>
<td>University Hospital Tübingen (Germany)</td>
<td></td>
</tr>
<tr>
<td>Choroideremia</td>
<td>REP1 gene therapy</td>
<td>Bascom Palmer</td>
<td>Phase 2</td>
<td>Bascom Palmer (Miami)</td>
<td></td>
</tr>
<tr>
<td>Choroideremia</td>
<td>REP1 gene therapy</td>
<td>Nightstar</td>
<td>Phase 2</td>
<td>• Moorfields Eye Hospital (UK) • Oxford University (UK)</td>
<td></td>
</tr>
<tr>
<td>Choroideremia</td>
<td>REP1 gene therapy</td>
<td>Spark</td>
<td>Phase 1/2</td>
<td>• Children’s Hospital of Philadelphia • University of Pennsylvania • Massachusetts Eye &amp; Ear Infirmary</td>
<td></td>
</tr>
<tr>
<td>Choroideremia</td>
<td>REP1 gene therapy</td>
<td>University Hospital Tübingen</td>
<td>Phase 2</td>
<td>University Hospital Tübingen (Germany)</td>
<td></td>
</tr>
<tr>
<td>LCA</td>
<td>Antisense oligonucleotide for CEP290 (c.2991+1655A&gt;G mutation)</td>
<td>ProQR</td>
<td>Phase 1/2</td>
<td>• University of Iowa • University of Pennsylvania • Ghent University Hospital (Belgium)</td>
<td></td>
</tr>
<tr>
<td>LCA and RP</td>
<td>RPE65 gene therapy</td>
<td>Spark</td>
<td>Completed Phase 3</td>
<td>• Children's Hospital of Philadelphia • University of Iowa</td>
<td></td>
</tr>
<tr>
<td>Retinoschisis</td>
<td>RS1 gene therapy</td>
<td>AGTC</td>
<td>Phase 1/2</td>
<td>Eight U.S. sites</td>
<td></td>
</tr>
<tr>
<td>Retinoschisis</td>
<td>RS1 gene therapy</td>
<td>National Eye Institute</td>
<td>Phase 1/2</td>
<td>National Eye Institute (Bethesda)</td>
<td></td>
</tr>
<tr>
<td>RP (Recessive)</td>
<td>PDE6B gene therapy</td>
<td>Horama</td>
<td>Phase 1/2</td>
<td>Nantes University Hospital (France)</td>
<td></td>
</tr>
<tr>
<td>RP</td>
<td>Optogenetic gene therapy</td>
<td>Allergan</td>
<td>Phase 1/2</td>
<td>Retina Foundation of the Southwest (Dallas)</td>
<td></td>
</tr>
<tr>
<td>RP (X-Linked)</td>
<td>RPGR gene therapy</td>
<td>MeiraGTx</td>
<td>Phase 1/2</td>
<td>Moorfields Eye Hospital (UK)</td>
<td></td>
</tr>
<tr>
<td>RP (X-Linked)</td>
<td>RPGR gene therapy</td>
<td>Nightstar</td>
<td>Phase 1/2</td>
<td>• Manchester Royal Eye Hospital (UK) • Oxford Eye Hospital (UK)</td>
<td></td>
</tr>
<tr>
<td>Stargardt disease</td>
<td>ABCA4 gene therapy</td>
<td>Sanofi</td>
<td>Phase 1/2</td>
<td>• Three U.S. sites • One French site</td>
<td></td>
</tr>
<tr>
<td>Usher type 1B</td>
<td>MYO7A gene therapy</td>
<td>Sanofi</td>
<td>Phase 1/2</td>
<td>• Oregon Health &amp; Science University • Hôpital des Quinze-Vingts (France)</td>
<td></td>
</tr>
</tbody>
</table>

Notes:

- Visit www.ClinicalTrials.gov for additional trial information including study contacts.
- The list is for select trials – not all clinical trials for retinal diseases are included.
- Always consult your physician before trying a new therapy or considering a clinical trial.
Treasurer’s Report

Haynes Lea, Treasurer

I am pleased to provide you the statement of activities and financial position for the Foundation Fighting Blindness fiscal year ending June 30, 2017.

We are especially grateful for the generous support of our donors. Their generosity has put the Foundation in a strong financial position to seed the important early research that will discover the next cure, maintain high levels of clinical research funding, and respond to breakthrough opportunities as they arise.

Our stewardship of the substantial funds raised through the Gordon and Llura Gund Family Challenge is guided by our strategic plan. Developed by FFB’s Research Oversight Committee, the strategic plan calls for the investment of $20 million in translational and proof-of-concept research each year for the next five years. Two projects initiated this past year involved commitments of up to $7.5 million each, leveraged with funds from other investors, to get patients into Phase 2 clinical trials. We are beginning to see grants made decades ago culminate in FDA applications for approval of actual treatments. In addition, thanks to our donors, we are now able to invest at dollar levels that can push these projects through to the clinic.

The application of nonprofit accounting principles to our financial statements creates two anomalies that merit additional explanation. These result from a combination of the pace of funding research commitments and the great success of the Gund Family Challenge in generating an unprecedented level of multiyear pledges.

Our audited financial statements indicate we have future obligations for grant payments of only $10 million, which suggests a relatively high level of net assets. In reality, we have binding commitments and reserves for identified, milestone-based research spending totaling $57.5 million. The funding for the additional $47.5 million in grant commitments and clinical trial-related costs is subject to certain scientific milestones, however; and under generally accepted accounting principles, these obligations may not be reflected as liabilities on our balance sheet until the milestones are met. If any milestones are not met, the funds committed to that research will be redeployed into other research worthy of our support.

Meanwhile, the Gund Family Challenge generated substantial pledges payable over multiple years. Accounting rules require that we record all pledged revenue in the years the pledges are made rather than as the pledges are actually paid or as research projects are funded. As a result, the funding of research projects creates a deficit for the current fiscal year even when the projects are funded out of contributions collected during the same year. As additional information, we have presented on the following page our statement of activities and financial position based on a modified accrual basis to reflect campaign cash intake and research outlays and commitments.

In sum, the Foundation has the financial resources and the strategic partnerships within the inherited retinal disease research community to continue to be the unparalleled leader driving cures to the clinic and the marketplace. With the continued generosity of our donors, the vision and expertise of our research team, and the energy and leadership of our new chief executive officer, we are excited to be able to make the significant investments necessary to fulfill our mission.

With heartfelt thanks to all our donors, volunteers, staff, and researchers,

Haynes P. Lea
Unaudited, Modified Accrual Basis

Statement of Activities

REVENUE AND SUPPORT
Contributions.................................................. 28,237,000*
Special events, net of direct.......................... 7,512,000
Bequests ......................................................... 3,655,000
Other revenue ................................................... 658,000
Total Revenue ................................................ $40,062,000

EXPENSES
Research .......................................................... 27,697,000*
Public health information ....................... 1,609,000
Management ..................................................... 2,842,000
Fundraising ........................................................ 7,223,000
Total Expenses ................................................ $39,371,000

Total Change in Net Assets ......................... $691,000*

Statement of Financial Position

ASSETS
Cash and investments ........................................ 106,919,000
Other assets ....................................................... 2,397,000*
Trusts and other funds .................................... 7,848,000
Fixed assets, net ................................................. 1,558,000
Total Assets ..................................................... $118,722,000

LIABILITIES
Accounts payable and accrued liabilities ............. 806,000
Research grants payable .................................. 58,168,000*
Deferred revenue ............................................. 1,348,000
Liabilities under trusts and other funds ............ 1,668,000
Total Liabilities ................................................ $61,990,000

NET ASSETS
Total net assets ............................................... 56,732,000*
Total Liabilities and Net Assets ....................... $118,722,000

* Does not reflect audited results in accordance with Generally Accepted Accounting Principles. Full audited financial statements are available at www.FightBlindness.org.

Year Ahead—Target Spending Allocations

70% Research Including Grants
17% Fundraising
7% Public Health Education
6% Administration
2017 Research Grants

2017 Research Investments

In its focused pursuit of preventions, treatments, and cures for the entire spectrum of retinal degenerative diseases, the Foundation evaluates and selects for support a diverse research portfolio. That portfolio is focused on six priority areas: genetics, gene therapy, the cellular mechanisms of retinal diseases, clinical structure and functional relationships, novel medical therapy, and regenerative medicine.

2017 New Commitments

Research Center grant funding ......................... 4,991,888
Individual Investigator grant funding ............... 3,370,795
Alan Laties Career Development grant funding ..... 1,635,000
Clinical Research Institute clinical studies and grant funding .............................................. 15,000,000

Total 2017 funding: ........................................ $24,997,683

For a complete list of all 2017 Foundation Fighting Blindness grant recipients, please visit: www.blindness.org/funded-grants.
Board of Directors

OFFICERS

David Brint  
Chairman  
Co-Founder and Principal  
Brinshore Development  
Northbrook, Illinois

Joel Davis  
Vice Chairman, Major Gifts  
Bethesda, Maryland

Edward Russnow  
Vice Chairman, Development  
President  
MAC Products, Inc.  
Kearny, New Jersey

Jonathan Steinberg, MD  
Vice Chairman, Research  
Professor of Medicine  
University of Rochester School of Medicine and Dentistry  
Rochester, New York

Warren Thaler  
Vice Chairman,  
Board Development & Communications  
Ardmore, Pennsylvania

Haynes Lea  
Treasurer  
Partner  
Robinson, Bradshaw & Hinson, PA  
Charlotte, North Carolina

Yvonne Chester  
Secretary  
Napa, California

DIREKTORS

Gordon Gund  
Co-Founder, Chairman Emeritus  
Chairman and CEO  
Gund Investment Corporation  
Princeton, New Jersey

Steve Alper  
Managing Director  
Stifel Financial  
New York, New York

Edward Babin  
President  
Metro Fire Protection  
Broomall, Pennsylvania

William Carty  
Cape Coral, Florida

Jason Ferreira  
Owner  
Ferreira Foodtown  
Greater New York City Area

Marilyn Green  
Owner  
Marilyn’s Agency  
Greensboro, North Carolina

Robert Heidenberg  
President and CEO  
Heidenberg Properties Group  
Closter, New Jersey

Janni Lehrer-Stein  
San Francisco, California

Bradford Manning  
Owner/Founder  
Two Blind Brothers  
New York, New York

Evan Mittman  
Armonk, New York

Karen Petrou  
Co-Founder and Managing Partner  
Federal Financial Analytics, Inc.  
Washington, DC

Maryrose Sylvester  
President and CEO  
Current, powered by GE  
Boston, Massachusetts
Scientific Advisory Board

CHAIR

Jacque Duncan, MD
Professor of Clinical Ophthalmology
Beckman Vision Center
University of California, San Francisco

VICE CHAIRS

Stephen P. Daiger, PhD
TS Matney Professor, Environmental and Genetic Sciences
Human Genetics Center
University of Texas Health Science Center

Frederick Ferris, III, MD
Clinical Director
National Eye Institute

John Flannery, PhD
Associate Director, Helen Wills Neuroscience Institute
University of California at Berkeley

Alan M. Laties, MD
Professor, Ophthalmology in Neurology
Department of Ophthalmology
University of Pennsylvania Medical School

Eric A. Pierce, MD, PhD
Director, Ocular Genomics Institute
Massachusetts Eye and Ear Infirmary
Harvard Medical School

José A. Sahel, MD
Professor and Chairman
Department of Ophthalmology
University of Pittsburgh School of Medicine

Richard G. Weleber, MD
Professor, Ophthalmology
Department of Molecular and Medical Genetics
Oregon Health Sciences University

Marco Zarbin, MD, PhD
Professor and Chair, Institute of Ophthalmology and Visual Science
Rutgers New Jersey Medical School

MEMBERS

Gustavo Aguirre, VMD, PhD, PhD (hc)
Professor, Medical Genetics and Ophthalmology
School of Veterinary Medicine
University of Pennsylvania

Bela Anand-Apte, MBBS, PhD
Professor, Cell Biology
Cole Eye Institute
Cleveland Clinic Foundation

John D. Ash, PhD
Associate Professor, Ophthalmology
University of Florida College of Medicine

Isabelle Audo, MD, PhD
Group Leader, Department of Genetics, Institut de la Vision
Consultant, Reference Centre for Rare Diseases at CHNO, Quinze-Vingts
Paris, France

Radha Ayyagari, PhD
Associate Professor, Ophthalmology
Shiley Eye Center
University of California, San Diego

William A. Beltran, DVM, PhD
Associate Professor, Ophthalmology
School of Veterinary Medicine
University of Pennsylvania
Scientific Advisory Board

Paul S. Bernstein, MD, PhD  
Professor, Ophthalmology and Visual Sciences  
Moran Eye Center, University of Utah

David G. Birch, PhD  
Director, Rose-Silverthorne Retinal Degenerations Laboratory  
Retina Foundation of the Southwest

Catherine Bowes Rickman, PhD  
Associate Professor, Department of Ophthalmology  
Duke University Medical Center

Frans P.M. Cremers, PhD  
Professor, Department of Human Genetics  
Radboud University Nijmegen Medical Centre

Eugene de Juan, Jr., MD  
Jean Kelly Stock Distinguished Professor  
Beckman Vision Center  
University of California, San Francisco

Lucian V. Del Priore, MD, PhD  
Professor and Chair, Department of Ophthalmology and Visual Science  
Yale University School of Medicine

Debora Farber, PhD  
Professor, Ophthalmology  
Jules Stein Eye Institute  
University of California, Los Angeles

G. Jane Farrar, PhD  
Professor, Genetics  
Smurfit Institute of Genetics  
Trinity College Dublin

Gerald A. Fishman, MD  
Director, The Pangere Center for Hereditary Retinal Diseases  
The Chicago Lighthouse for People Who are Blind or Visually Impaired

Steven J. Fliesler, PhD  
Professor, Vice-Chair, and Director of Research  
Department of Ophthalmology  
University at Buffalo/The State University of New York (SUNY-UB)

David M. Gamm, MD, PhD  
Associate Professor, Ophthalmology and Visual Sciences  
University of Wisconsin-Madison

Morton F. Goldberg, MD  
Professor, Ophthalmology  
Wilmer Eye Institute  
Johns Hopkins Hospital

William W. Hauswirth, PhD  
Professor, Ophthalmology and Molecular Genetics  
University of Florida College of Medicine

Elise Héon, MD, FRCSC  
Ophthalmologist-in-Chief, Ophthalmology and Vision Sciences  
The Hospital for Sick Children  
University of Toronto  
Toronto, Canada

Joe G. Hollyfield, PhD  
Director, Department of Ophthalmic Research  
Cole Eye Institute  
Cleveland Clinic Foundation

Leslie G. Hyman, PhD  
Professor, Department of Preventive Medicine  
Stony Brook University Medical Center

Alessandro Iannaccone, MD, MS  
Professor, Ophthalmology  
Duke University Medical Center  
Duke Eye Center

Samuel G. Jacobson, MD, PhD  
Director, Center for Hereditary Retinal Degenerations and Retinal Function Department  
Scheie Eye Institute  
University of Pennsylvania

Tiansen Li, PhD  
Neurobiology-Neurodegeneration and Repair Laboratory  
National Eye Institute  
National Institutes of Health

Roderick R. McInnes, MD, PhD  
Director, Lady Davis Institute  
Jewish General Hospital

Muna I. Naash, PhD  
John S. Dunn Professor, Biomedical Engineering  
Department of Biomedical Engineering  
University of Houston

Jeremy Nathans, MD, PhD  
Professor, Molecular Biology and Genetics  
Johns Hopkins University School of Medicine

Gary D. Novack, PhD  
President  
PharmaLogic Development, Inc.
Scientific Advisory Board

Mark Pennesi, MD, PhD
Associate Professor
Chief, Ophthalmic Genetics Division
Oregon Health and Science University

Thomas Reh, PhD
Director, Neurobiology and Behavior
Department of Biological Structure
University of Washington

Bärbel M. Rohrer, PhD
Professor, Ophthalmology and Neurosciences
Medical University of South Carolina

Johanna M. Seddon, MD, ScM
Director, Ophthalmic Epidemiology and Genetics Service
New England Eye Center
Tufts University School of Medicine

Hendrik P.N. Scholl, MD, MA
Professor and Chairman, Ophthalmology
University of Basel
Basel, Switzerland

Janet R. Sparrow, PhD
Professor, Ophthalmic Science
Department of Pathology and Cell Biology
Columbia University

Douglas Vollrath, MD, PhD
Associate Professor, Genetics
Stanford University School of Medicine

David S. Williams, PhD
Director, Jules Stein Eye Institute
UCLA School of Medicine

Michael J. Young, PhD
Director, Minda de Gunzburg Research Center for Ocular Regeneration
Schepens Eye Research Institute
Department of Ophthalmology
Harvard Medical School

Donald J. Zack, MD, PhD
Professor, Genetic Engineering and Molecular Ophthalmology
Wilmer Eye Institute
Johns Hopkins University School of Medicine

Robert E. Anderson, MD, PhD
Department of Ophthalmology
University of Oklahoma Health Sciences Center

Jean Bennett, MD, PhD
Professor, F.M. Kirby Center for Molecular Ophthalmology
Scheie Eye Institute
University of Pennsylvania School of Medicine

Dean Bok, PhD
Director, Retinal Cell Biology Laboratory
Jules Stein Eye Institute
University of California, Los Angeles

John E. Dowling, PhD
Professor, Ophthalmology
The Biological Laboratories
Harvard University

Gregory S. Hageman, PhD
Presidential Professor of Ophthalmology & Visual Sciences
John A. Moran Eye Center
University of Utah

William J. Kimberling, PhD
Director, Center for the Study and Treatment of Usher Syndrome
Father Flanagan’s Boys’ Home
Boys Town National Research Hospital

Matthew M. LaVail, PhD
Professor, Anatomy and Ophthalmology
Beckman Vision Center
University of California, San Francisco

Vincent H. L. Lee, PhD
Professor and Director
School of Pharmacy
Chinese University of Hong Kong

Edwin Stone, MD, PhD
Seamans-Hauser Chair in Molecular Ophthalmology
Department of Ophthalmology and Visual Sciences
University of Iowa Hospitals & Clinics

Russell N. Van Gelder, MD, PhD
Professor and Chair, Ophthalmology
Department of Ophthalmology
University of Washington

Andreas Wenzel, PhD
Medical Affairs Manager
Novartis Pharma
Bern, Switzerland

EMERITUS MEMBERS
National Trustees

David Alexander
Peter Alexander
Terry Pink Alexander
Pamela Allen
Julie Anderson
Gregory Austin
Hal Barron, MD
Daniel Bergstein
Jordan Bergstein
Beverly Berman
Thomas Bernardin
Joseph Bier
Jay Blackman
LuAnn Blackman
Aryeh Bourkoff
Betsy Bradley
Denice Brown
Steven Browne
Scott Burt
Melissa Campbell, MD
Patricia Campbell-Stichweh
Mindy Caplan
Shoshana Cardin
William Chatlos
Robert Cleveland
Alice Cohen, MD

Christopher Coleman
Joan Crowley
Peter Crowley
Thomas Curley
Glen Davidson
Daniel Day
Eugene de Juan, Jr., MD
David Detrisac, MD
Steven Dezii
Betty Dominick
James Dominick
Ralph Donnelly
Christina Fasser
Jennifer Ferreira
David Finkelstein
Harriet Finkelstein
Robert Finzi
William Fischer
Edward Gollob
Jane Gomez
Ramon Gomez
Dean Green
Bruce Grieve
Grant Gund
Lara Gund

Llura Gund
G. Zachary Gund
Lawrence Halperin, MD
Steve Hamby
Roger Horchow
Laura Hughes
Robert Hughes
William James, Jr.
Tracy Johns, EdD
Joseph Kahl
Judy Kahl
Alan Kahn
Anne Katcher
Gary Katcher
Mitch Katcher
Jody Kelly
Gil Kliman, MD
Ann Korologos
Louis Kreisberg
Sherri Kroonenberg
J. Gilmour Lake
Alan Landis
Elizabeth Lea
Abigail LeBlanc
Linda Lechner
Nathan Light
William Link, PhD
## National Trustees

<table>
<thead>
<tr>
<th>Davida Luehrs</th>
<th>Dale Pollak</th>
<th>Teri Ardleigh Swift</th>
</tr>
</thead>
<tbody>
<tr>
<td>April Lufriu</td>
<td>Nancy Pollak</td>
<td>Donna Burke Tehaan</td>
</tr>
<tr>
<td>Karen Luna</td>
<td>Louis Posen</td>
<td>Frank Trainor</td>
</tr>
<tr>
<td>Stephen Mack</td>
<td>Noah Rabinsky</td>
<td>Meredith Tyree</td>
</tr>
<tr>
<td>Kamal Majeed, PhD</td>
<td>Walter Raineri</td>
<td>Mark Valenziano</td>
</tr>
<tr>
<td>Bryan Manning</td>
<td>Mitch Reiter</td>
<td>Michelle Veloce</td>
</tr>
<tr>
<td>Ronald Massman</td>
<td>Kenneth Rietz</td>
<td>Lamar Villere</td>
</tr>
<tr>
<td>James Mattox</td>
<td>Holly Rush</td>
<td>David Walsh</td>
</tr>
<tr>
<td>Reston Mattox</td>
<td>John Saclarides</td>
<td>Peter Whinfrey</td>
</tr>
<tr>
<td>Beatrice Mayer</td>
<td>Melville Sahyun, PhD</td>
<td>John Wilson, Jr.</td>
</tr>
<tr>
<td>William McCaughey</td>
<td>Bruce Sawyer</td>
<td>William Woodall</td>
</tr>
<tr>
<td>James McNiel</td>
<td>Ginny Schott</td>
<td>Stephen Wynn</td>
</tr>
<tr>
<td>Wren McNiel</td>
<td>James Schott, PhD</td>
<td>Eric Zankman</td>
</tr>
<tr>
<td>Debi Mittman</td>
<td>Ira Schulman</td>
<td></td>
</tr>
<tr>
<td>Karen Montagnese</td>
<td>M. Rose Shane</td>
<td></td>
</tr>
<tr>
<td>Nicholas Montagnese</td>
<td>Deborah Shaw</td>
<td></td>
</tr>
<tr>
<td>Jason Morris</td>
<td>Jeremiah Shaw</td>
<td></td>
</tr>
<tr>
<td>Jill Morris</td>
<td>Moira Shea</td>
<td></td>
</tr>
<tr>
<td>Leslie Morris</td>
<td>Stuart Slotnick</td>
<td></td>
</tr>
<tr>
<td>Robert Morris</td>
<td>Iris Spiegel</td>
<td></td>
</tr>
<tr>
<td>Sean Moynihan</td>
<td>Reuven Spiegel</td>
<td></td>
</tr>
<tr>
<td>John Mozeliak</td>
<td>Alan Spiro</td>
<td></td>
</tr>
<tr>
<td>Jacob Myers</td>
<td>Martha Steele</td>
<td></td>
</tr>
<tr>
<td>Jack Nudel, MD</td>
<td>Barbara Stone</td>
<td></td>
</tr>
<tr>
<td>Harry Oakes</td>
<td>Jill Stone</td>
<td></td>
</tr>
<tr>
<td>Pat O’Callaghan, Sr.</td>
<td>Joel Stone</td>
<td></td>
</tr>
<tr>
<td>Igor Olenicoff</td>
<td>Michael Stone</td>
<td></td>
</tr>
</tbody>
</table>
SENIOR MANAGEMENT TEAM

Benjamin Yerxa, PhD  
*Chief Executive Officer*

Stephen Rose, PhD  
*Chief Research Officer*

Patricia Zilliox, PhD  
*Chief Drug Development Officer*

Valerie Navy-Daniels  
*Chief Development Officer*

Annette Hinkle, CPA  
*Chief Financial Officer*

Patricia Dudley  
*Chief Human Resources Officer*

HEADQUARTERS

7168 Columbia Gateway Drive, Suite 100  
Columbia, Maryland 21046  
410-423-0600

REGIONAL OFFICES

**Chicago**  
977 Lakeview Parkway, Suite 140  
Vernon Hills, IL 60061  
847-680-0100

**Los Angeles**  
10350 Santa Monica Blvd., Suite 250  
Los Angeles, CA 90025  
310-201-3005

**New York**  
80 Broad Street, Suite 3301  
New York, NY 10004  
212-244-1470

**Raleigh**  
4600 Marriott Drive, Suite 340  
Raleigh, NC 27612  
919-781-8014
National Chapters

NORTHEAST REGION

Boston, MA
Martha Steele, President

Long Island, NY
Nick and Karen Montagnese, Co-Presidents

New York City, NY
Carl Gruber, President

Philadelphia, PA
Heather Napolitano, President

Princeton, NJ
Llura Gund, President

Westchester, NY/Fairfield, CT

Western New York
Sarah Malburg, President

SOUTHERN REGION

Atlanta, GA

Baltimore, MD
Mindy Caplan, President

Charlotte, NC
Trent Scovell, President

Greensboro (Triad), NC
Tom Serrin, President

Jacksonville, FL
Adriann Keve, President

Montgomery County, MD
Eric Fulton, President

Nashville (Middle TN), TN

Northern Virginia
Davida Luehrs, President

Orlando, FL
Daniel Day, President

Raleigh-Durham, NC
Kristy Lee, President

South Carolina
Kelly Lucas, President

Tampa Bay, FL
April Lufriu, President

Virginia Beach (Hampton Roads)
Debra Laughlin, President

MIDWEST REGION

Chicago, IL
Tom Weber, President

Cincinnati, OH/N. Kentucky
Tim Smith, President

Cleveland, OH
Greg Dubeecky, President

Columbus, OH
Kevin Walker, President

Eastern Michigan
Kathy Marcarth, President

Ft. Wayne, IN
Rick Dahlstrom, President

Indianapolis, IN
Gil Iames, President

Kansas City, MO
Terry Super, President

Milwaukee, WI
Bonita Jordan, President

Minneapolis, MN
Julie Anderson, President

Pittsburgh, PA
Cara Delestienne, President

St. Louis, MO
Jason Morris, President

WESTERN REGION

Arizona
Jacque Olsen, President

Bay Area, CA
Jeffrey Libby, President

Dallas, TX
Neva Fairchild, President

Denver, CO
Carmen Swick, President

Fort Worth, TX
Dr. Sai Chavala, President

Houston, TX
Carley Colton, President

Los Angeles, CA

Orange County, CA
Randy Wechter, President

San Antonio, TX
Todd Dunn, President

San Diego, CA

Seattle, WA
Mike Hoag, President
2017 Snapshot

Northern Virginia VisionWalk

Fashion and Finance Ball, New York City

Llura and Gordon Gund at the Investing in Cures Summit